



In vivo Antibodies Functional-Grade



Immune Checkpoint | Cell Depletion | Cancer Immunology

Ultra Low Endotoxin In vivo mAbs

Extremely low endotoxin levels (≤ 0.5 EU/mg - ≤ 1 EU/mg) for in vivo mouse studies or sensitive in vitro experiments

Validated

Immune checkpoint blockade, neutralization, stimulation, cell depletion, ELISA, FC, ICC, IHC, IP, WB, CODEX®, CyTOF®

Highly Pure

No preservatives, stabilizers, carrier proteins & made using sterilized PBS without K⁺ and Ca²⁺.

Super Consistent

cGMP-grade & extensively quality controlled with minimal protein A leaching and low aggregation ensuring excellent Lot-to-Lot reproducibility

Product Name	5mg Pack Sizes		25mg Pack Sizes		50mg Pack Sizes	
	Code	Promo Price	Code	Promo Price	Code	Promo Price
Anti-Mouse PD-1 [29F.1A12] In Vivo mAb - Low Endotoxin	RGEIVMB0031-5mg	CHF 321.85	RGEIVMB0031-25mg	CHF 1021.70	RGEIVMB0031-50mg	CHF 1607.80
Anti-Human CD3 [UCHT-1] In Vivo mAb - Low Endotoxin	RGEIVMB0117-5mg	CHF 321.85	RGEIVMB0117-25mg	CHF 1021.70	RGEIVMB0117-50mg	CHF 1607.80
Anti-Mouse CD4 [GK1.5] In Vivo mAb - Low Endotoxin	RGEIVMB0060-5mg	CHF 321.85	RGEIVMB0060-25mg	CHF 1021.70	RGEIVMB0060-50mg	CHF 1607.80
Anti-Mouse CD8b.2 In Vivo mAb - Low Endotoxin	RGEIVMB0093-5mg	CHF 321.85	RGEIVMB0093-25mg	CHF 1021.70	RGEIVMB0093-50mg	CHF 1607.80
Anti-Mouse CD8a (Ly2) In Vivo mAb - Low Endotoxin	RGEIVMB0068-5mg	CHF 321.85	RGEIVMB0068-25mg	CHF 1021.70	RGEIVMB0068-50mg	CHF 1607.80
Mouse IgG1 Isotype Control [HKSP] - Low Endotoxin	RGEIVMB0184-5mg	CHF 321.85	RGEIVMB0184-25mg	CHF 1021.70	RGEIVMB0184-50mg	CHF 1607.80
Mouse IgG2a Isotype Control - Low Endotoxin	RGEIVMB0188-5mg	CHF 321.85	RGEIVMB0188-25mg	CHF 1021.70	RGEIVMB0188-50mg	CHF 1607.80
Rat IgG2b Isotype Control - Low Endotoxin	RGEIVMB0200-5mg	CHF 321.85	RGEIVMB0200-25mg	CHF 1021.70	RGEIVMB0200-50mg	CHF 1607.80
Rat IgG2a Isotype Control - Low Endotoxin	RGEIVMB0199-5mg	CHF 321.85	RGEIVMB0199-25mg	CHF 1021.70	RGEIVMB0199-50mg	CHF 1607.80



Prices are net and without VAT
Special Offer valid from 01.01.24 until 30.09.24

SUPERIOR EFFICACY & QUALITY

Antibodies and isotypes tested

Independent comparison of the in vivo efficacy and tolerability of clones of mAbs anti-PD-1 [RMP1-14 and 29F.1A12], and isotype controls versus Vendor B using a CT26 syngeneic model (murine colorectal carcinoma derived from BALB/c mice). All antibodies had matching isotype controls, and phosphate-buffered saline (PBS) was used as a control.

ANTI-PD-1



Treatment	Tumor size Day 26 (mm ³)	TGI Day 26 (%)	P-value
Isotype	1197 ± 697	-	-
RMP1-14	470 ± 597	61	0.049
29F.1A12	395 ± 432	67	0.018

Treatment	Tumor size Day 26 (mm ³)	TGI Day 26 (%)	P-value
Isotype	1234 ± 670	-	-
RMP1-14	656 ± 704	47	0.114
29F.1A12	805 ± 939	35	0.312

Anti-PD-1 antibody clones (RMP1-14 and 29F.1A12) were more efficacious than Vendor B (Figure 1).

Highly Pure with Low Endotoxin Levels

Specifications	<i>in vivo</i> mAbs Low Endotoxin	<i>in vivo</i> mAbs Ultra Low Endotoxin
Binding validation determined by WB, FC or ELISA	Yes	Yes
Endotoxin level determined by the LAL method	≤ 1.0 EU/mg	≤ 0.5 EU/mg
Antibody aggregation screening by analytical SEC	≥ 95% monomer	≥ 98% monomer
Purity by SDS PAGE	≥ 95%	≥ 98%
Formulation for <i>in vivo</i> use	No Preservatives No stabilizers No carrier protein Sterile PBS pH 7.2 - No K ⁺ or CA ²⁺ Concentration: > 5mg/mL	No Preservatives No stabilizers No carrier protein Sterile PBS pH 7.2 - No K ⁺ or CA ²⁺ Concentration: > 5mg/mL
Murine pathogen screening	Not applicable, see Ultra Low Endotoxin functional grade antibodies	Pathogen tested (IMPACT1) (see table)

www.assaygenie.com/in-vivo-functional-grade-antibodies